{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-108624","form_type":"8-K","ticker":"IVVD","cik":"0001832038","company_name":"Invivyd, Inc.","filed_at":"2024-09-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.781534+00:00","generated_at":"2026-05-31T02:29:53.510900+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Invivyd provides virology data showing PEMGARDA neutralization potency stable against current SARS-CoV-2 variants","bullets":["In vitro neutralization potency of PEMGARDA against KP.3.1.1 and LB.1 variants remains in-line with prior predominant variants dating to 2022.","Structural analysis shows 19-key-amino-acid pemivibart binding site has de minimis mutational change and 99%+ stability since Omicron BA.1.","Emerging variants XEC and LP.1 have mutations distal to binding site, not expected to meaningfully alter pemivibart activity; routine testing follows.","Data from independent LabCorp Monogram Biosciences lab; company expects sustained neutralization based on structural biology."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-108624","json":"https://secwatch.observer/filing/0000950170-24-108624.json","markdown":"https://secwatch.observer/filing/0000950170-24-108624.md","text":"https://secwatch.observer/filing/0000950170-24-108624.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1832038/000095017024108624/0000950170-24-108624-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1832038/000095017024108624/ivvd-20240923.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T02:29:53.510900+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}